Head And Neck Cancer

Acupuncture benefitted patients with head and neck cancer who had radiation-induced xerostomia, according to study results presented at ASCO Annual Meeting.

CHICAGO — A sequential schedule of fixed-dose pembrolizumab with chemoradiotherapy conferred numerically higher PFS rates vs. concurrent timing of the drug among patients with locally advanced head and neck cancer, study results showed.

CHICAGO — Docetaxel prolonged DFS and OS when added to radiation for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, according to study results presented at ASCO Annual Meeting.

CHICAGO — Intensity-modulated radiotherapy conferred disease control and survival outcomes comparable to concurrent chemoradiotherapy but with less toxicity among patients with low-risk nasopharyngeal carcinoma, according to study results.

The inclusion of a smoking cessation tool into electronic health records increased self-reported patient quit rates by more than 5 percentage points, according to study results.

Entrectinib demonstrated durable systemic and intracranial responses in patients with NTRK fusion-positive solid tumors, according to study results published in Clinical Cancer Research.

Capecitabine maintenance therapy significantly prolonged PFS among patients with newly diagnosed metastatic nasopharyngeal carcinoma who achieved disease control after capecitabine-containing induction chemotherapy, according to a study.

Paclitaxel plus fluorouracil did not demonstrate OS superiority over paclitaxel plus cisplatin or paclitaxel plus carboplatin in definitive chemoradiation for locally advanced esophageal squamous cell carcinoma.

DALLAS — Microscopic extranodal extension appeared associated with shorter survival among patients with oral cavity squamous cell carcinoma, according to study results.

DALLAS — Treatment modality for HPV-positive oropharyngeal squamous cell carcinoma varied considerably by facility type, according to study results.